公开(公告)号：KR1020100024055A

公开(公告)日：2010-03-05

申请号：KR1020080082732

申请日：2008-08-25

Applicant: 단국대학교 산학협력단

Inventor： 이성욱 ,  송민선 ,  김인후 ,  정진숙

IPC: C12N15/861 ,  C12N15/09

CPC classification number: C12N15/1135 ,  A61K38/00 ,  C12N15/86 ,  C12N2310/124 ,  C12N2710/10343 ,  C12N2830/008 ,  C12N2840/445

Abstract: PURPOSE: A recombinant adenovirus containing a trans-splicing ribozyme targeting tissue-specific promoter and a cancer-specific gene is provided to ensure improved treatment efficiency for gene target tissue and to be used as an anticancer drug or a cancer diagnosis agent. CONSTITUTION: A recombinant adenovirus contains: a tissue-specific promoter; a trans-splicing ribozyme which is operably linked to the promoter; and a therapeutic gene linked to a 3'-exon of ribozyme or a reporter gene. A cancer-specific gene is hTERT[human Telomerase Reverse Transcriptase] mRNA[messenger RNA], AFP[alphafetoprotein] mRNA, CEA[carcinoembryonic antigen] mRNA, PSA[Prostate-specific antigen] mRNA, or CKAP2[Cytoskeleton-associated protein 2] mRNA. The ribozyme is a trans-splicing group I ribozyme which specifically targets hTERT mRNA. A pharmaceutical composition for anticancer drugs contains the recombinant adenovirus as an active ingredient. A method for imaging cancer comprises: a step of introducing the recombinant adenovirus to cancer cells; and a step of detecting a reporter protein in the cancer cells.

Abstract translation: 目的：提供一种重组腺病毒，其含有靶向组织特异性启动子和癌特异性基因的转拼核糖酶，以确保提高基因靶组织的治疗效率，并用作抗癌药物或癌症诊断剂。 构成：重组腺病毒包含：组织特异性启动子; 与启动子可操作地连接的转拼核酶; 和与核酶或报告基因的3'-外显子连接的治疗基因。 癌症特异性基因是hTERT [人类端粒酶逆转录酶] mRNA [信使RNA]，AFP [甲胎蛋白] mRNA，CEA [癌胚抗原] mRNA，PSA [前列腺特异性抗原] mRNA或CKAP2 [细胞骨架相关蛋白2] mRNA的表达。 核酶是特异性靶向hTERT mRNA的转拼组I核酶。 用于抗癌药物的药物组合物含有重组腺病毒作为活性成分。 用于癌症成像的方法包括：将重组腺病毒引入癌细胞的步骤; 以及检测癌细胞中报道蛋白的步骤。